Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) announced positive updates from its Phase 1/2 trial of CA-4948, an IRAK4 kinase inhibitor, at the EHA 2021 Congress. The trial targets patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings show effective dose at 300 mg BID, with significant hematologic recovery and objective responses in patients with spliceosome or FLT3 mutations. CA-4948 also demonstrated synergistic activity in preclinical studies when combined with azacitidine and venetoclax. The company plans to initiate combination studies later this year.
Curis (NASDAQ: CRIS) announced a virtual KOL event on June 11, 2021, to discuss progress on CA-4948, a first-in-class IRAK4 kinase inhibitor. The event will include updated data from the Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), initially presented at the European Hematology Association 2021 Virtual Congress. Curis CEO James Dentzer and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center will lead the discussion, with a Q&A session to follow. A live webcast will be available on Curis' website.
Curis, Inc. (NASDAQ: CRIS) announced a virtual symposium titled "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond", occurring on June 18, 2021. The event will feature discussions on the emerging checkpoint molecule VISTA, its implications in various diseases, and ongoing development programs, including Curis's anti-VISTA antibody, CI-8993, currently in clinical trials. Notable speakers include Dr. Randolph Noelle and Dr. Padmanee Sharma. Attendees will explore topics such as checkpoint therapy, VISTA's role in the tumor microenvironment, and advances in clinical development.
Curis, a biotechnology company specializing in cancer therapeutics, announced that its CEO, James Dentzer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET. The event will be available via live webcast on Curis' investor website, with a replay for 90 days post-event. Curis is known for its research in immuno-oncology and precision oncology, including ongoing trials for CA-4948, targeting various forms of cancer.
Curis, Inc. (NASDAQ: CRIS) reported its Q1 2021 results, marking a net loss of $9.9 million or $0.11 per share. Revenues declined to $2.2 million from $2.7 million in Q1 2020. Operational highlights include progress on CA-4948, which expanded into new clinical trials, receiving Orphan Drug designation from the FDA for AML and MDS, and promising early results in ongoing studies. Cash reserves stood at $168.4 million, expected to sustain operations into 2024. The company plans to share more clinical data at the EHA Congress and future trials in the second half of 2021.
Curis, Inc. (NASDAQ: CRIS) announced two abstracts for CA-4948 accepted for presentation at the European Hematology Association 2021 Virtual Congress from June 9-17, 2021. CA-4948 is an IRAK4 inhibitor in a Phase 1/2 study targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Key findings from 15 patients included a 89% blast reduction in evaluable patients and notable hematologic responses. Curis anticipates presenting additional data on safety and efficacy at the congress.
Curis, a biotechnology company focused on cancer therapeutics, will release its first quarter 2021 financial results on May 12, 2021, after US market close. A conference call is scheduled for 4:30 pm ET on the same day to discuss the results. The company is engaged in multiple collaborations and clinical trials, including CA-4948 for non-Hodgkin lymphoma and other conditions, as well as ongoing trials for CI-8993. Investors can access the call via phone or the Curis website.
Curis, Inc. (NASDAQ: CRIS) announced that the FDA has granted Orphan Drug designation for CA-4948, a small molecule inhibitor targeting IRAK4, primarily for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This designation offers benefits like seven years of market exclusivity and FDA support in clinical trials. The drug has shown broad clinical activity in Phase 1 trials for relapsed or refractory AML/MDS. CEO James Dentzer highlighted this as a significant milestone in addressing rare hematological malignancies.
Curis, Inc. (NASDAQ: CRIS) announced on April 1, 2021, the grant of inducement stock options for 167,300 shares to five new employees. The options have a ten-year term, with an exercise price equal to the closing stock price on the grant date. Vesting occurs over four years, starting with 25% after one year. This grant is meant to incentivize new hires and is categorized as an inducement award outside the company’s existing stock plan. Curis focuses on cancer therapeutics and has collaborations with various partners for drug development.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 am ET. A live webcast will be available on the company's website, with a replay accessible for 90 days. Curis has ongoing collaborations in immuno-oncology, including testing CA-4948 in lymphomas and leukemia, and developing CI-8993 for solid tumors. The company also collaborates with Genentech for Erivedge, a treatment for advanced basal cell carcinoma.